Contents

Search

tenecteplase (TNKase)

Modified version of tissue plasminogen activator (tPA, Activase) with 3 amino acid substitutions. Advantages: 1) longer 1/2 life than tPA 2) may be given as a single bolus injection over 5 seconds 3) seems to cause fewer bleeding complications than tPA a) less extra-cranial bleeding b) similar risk of intracranial bleeding & stroke Dosage: - 30-50 mg IV bolus (single dose) - for use with unfractionated heparin or LMW heparin Adverse effects: - intracerebral hemorrhage 0.9% Mechanism of action: - relatively fibrin-selective plasminogen activator [3]

Related

thrombolytic therapy

General

recombinant tissue plasminogen activator (TPA, t-PA, rt-PA,)

References

  1. Prescriber's Letter 7(7):38 2000
  2. Department of Veterans Affairs, VA National Formulary
  3. Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 17. American College of Physicians, Philadelphia 2009, 2012, 2015